Proteasome regulator marizomib (NPI-0052) Exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 2, 2011, Pages 479-486

  Obaidat, Amanda ^a   Weiss, Jeffrey ^c   Wahlgren, Brett ^a   Manam, Rama R ^c   Macherla, Venkat R ^c   McArthur, Katherine ^c   Chao, Ta Hsiang ^c   Palladino, Michael A ^c   Lloyd, G Kenneth ^c   Potts, Barbara C ^c   Enna, Salvatore J ^a,c   Neuteboom, Saskia T C ^a   Hagenbuch, Bruno ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^c Nereus Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(CYCLOHEX 2 ENYL)(HYDROXY)METHYL] 4 ETHYL 5 METHYL 6 OXA 2 AZABICYCLO[3.2.0]HEPTANE 3,7 DIONE; 1 [(CYCLOHEX 2 ENYL)(HYDROXY)METHYL] 4,5 DIMETHYL 6 OXA 2 AZABICYCLO[3.2.0]HEPTANE 3,7 DIONE; 1 [(CYCLOHEX 2 ENYL)(HYDROXY)METHYL] 5 METHYL 4 PROPYL 6 OXA 2 AZABICYCLO[3.2.0]HEPTANE 3,7 DIONE; 2 1 [[(CYCLOHEX 2 ENYL)(HYDROXY)METHYL] 5 METHYL 3,7 DIOXO 6 OXA 2 AZABICYCLO[3.2.0]HEPTAN 4 YL]ETHYL BENZENESULFONATE; 2 1 [[(CYCLOHEX 2 ENYL)(HYDROXY)METHYL] 5 METHYL 3,7 DIOXO 6 OXA 2 AZABICYCLO[3.2.0]HEPTANE 4 YL] METHANESULFONATE; ABC TRANSPORTER; NPI 0047; NPI 2063; NPI 2080; NPI 2150; NPI 2151; PROTEASOME; SALINOSPORAMIDE A; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFUSION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LACTAMS; LACTONES; P-GLYCOPROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRROLES;

EID: 79954990288     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.177824     Document Type: Article

References (22)

1. Adams J (2004) The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360. (Pubitemid 38579481)
2. Anderson KC (2004) Bortezomib therapy for myeloma. Curr Hematol Rep 3:65-66.
3. Bochtler M, Ditzel L, Groll M, Hartmann C, and Huber R (1999) The proteasome. Annu Rev Biophys Biomol Struct 28:295-317. (Pubitemid 29319261)
4. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, et al. (2005a) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8:407-419. (Pubitemid 41579835)
5. Chauhan D, Hideshima T, and Anderson KC (2005b) Proteasome inhibition in multiple myeloma: Therapeutic implication. Annu Rev Pharmacol Toxicol 45:465-476.
6. Denora N, Potts BC, and Stella VJ (2007) A mechanistic and kinetic study of the β-lactone hydrolysis of Salinosporamide A (NPI-0052), a novel proteasome inhibitor. J Pharm Sci 96:2037-2047. (Pubitemid 47280100)
7. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, and Fenical W (2003) Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 42:355-357. (Pubitemid 36176323)
8. Groll M, Huber R, and Potts BC (2006) Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 128:5136-5141.
9. Groll M, McArthur KA, Macherla VR, Manam RR, and Potts BC (2009) Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition. J Med Chem 52:5420-5428.
10. Gui C, Miao Y, Thompson L, Wahlgren B, Mock M, Stieger B, and Hagenbuch B (2008) Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 584:57-65.
11. Hideshima T and Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2:927-937. (Pubitemid 37328894)
12. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, and Pazdur R (2007) Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13:5291-5294. (Pubitemid 47510352)
13. Kisselev AF, Garcia-Calvo M, Overkleeft HS, Peterson E, Pennington MW, Ploegh HL, Thornberry NA, and Goldberg AL (2003) The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 278:35869-35877. (Pubitemid 37139904)
14. Macherla VR, Mitchell SS, Manam RR, Reed KA, Chao TH, Nicholson B, Deyanat-Yazdi G, Mai B, Jensen PR, Fenical WF, et al. (2005) Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 48:3684-3687. (Pubitemid 40776841)
15. Manam RR, Macherla VR, and Potts BCM (2007) Stereoselective enzymatic reduction of keto-salinosporamide to (β)-salinosporamide A (NPI-0052). Tetrahed Lett 48:2537-2540. (Pubitemid 46356466)
16. Manam RR, McArthur KA, Chao TH, Weiss J, Ali JA, Palombella VJ, Groll M, Lloyd GK, Palladino MA, Neuteboom ST, et al. (2008) Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides. J Med Chem 51:6711-6724.
17. Mitchell SS, Nicholson B, Teisan S, Lam KS, and Potts BC (2004) Aureoverticillactam, a novel 22-atom macrocyclic lactam from the marine actinomycete Streptomyces aureoverticillatus. J Nat Prod 67:1400-1402. (Pubitemid 39145651)
18. Reed KA, Manam RR, Mitchell SS, Xu J, Teisan S, Chao TH, Deyanat-Yazdi G, Neuteboom ST, Lam KS, and Potts BC (2007) Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome. J Nat Prod 70:269-276. (Pubitemid 46447642)
19. Sun H, Johnson DR, Finch RA, Sartorelli AC, Miller DW, and Elmquist WF (2001) Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun 284:863-869. (Pubitemid 32924727)
20. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, and Namiki M (2007) The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 67:955-967. (Pubitemid 46828929)
21. Williams PG, Buchanan GO, Feling RH, Kauffman CA, Jensen PR, and Fenical W (2005) New cytotoxic salinosporamides from the marine actinomycete Salinispora tropica. J Org Chem 70:6196-6203. (Pubitemid 41076500)
22. Zalcberg J, Hu XF, Slater A, Parisot J, El-Osta S, Kantharidis P, Chou ST, and Parkin JD (2000) MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis 3:66-75. (Pubitemid 30663591)